Nicholson JK, Lindon JC, Holmes E. ’Metabonomics
’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica, 1999, 29(11): 1181-9.
2 German J, Bauman D, Burrin D, et al. Metabolomics in the opening decade of the 21st Century: building the roads to individualized health. J Nutr, 2004, 134(10): 2729-32.
4 Chen JL, Tang HQ, Hu JD, et al. Metabolomics of gastric cancer metastasis detected by gas chromatography and mass speetrometry. J Gastroenterol. 2010, 16(46): 5874-80.
5 Hu JD, Tang HQ, Zhang Q, et al. Prediction of gastric cancer metastasis through urinary metabolomic investigation using GC/MS. World J Gastroenterol, 2011, 17(6): 727-34.
7 Ikeda A, Nishiumi S, Shinohara M, et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr, 2012, 26(5): 548-58.
8 Wang B, Chen D, Chen Y, et al. Metabonomie profiles discriminate hepatocellular pxtrcinonla from liver cirrhosis by uhraperformance liquid chromatography-mass spectrometry. J Proteome Res, 2012, 11(2): 1217-27.
9 Tan Y, Yin P, Tang L, et al. Metabolomics study of stepwise hepatocarcinogenesis from the model mts to patients：potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics, 2012, 11(2): M111.010694.
10 Zhang J, Liu L, Wei S, et al. Metabolomics study of esophageal adenocarcinoma. J Thorac Cardiovasc Surg, 2011, 141(2): 469-75.
11 Zhang J, Bowers J, Liu L, et al. Esophageal cancer metabolite biomarkers detected by LCMS and NMR methods. PLoS One, 2012, 7(1): e30181.
12 Davis VW, Schiller DE, Eurich D, et al. Urinary metabolomic signature of esophageal cancer and Barrett’s esophagus. J Surg Orwol, 2012, 10(1): 271-83.
13 Hasim A, Ma H, Mamrimin B, et al. Revealing the metabolomic variation of EC using 1H-NMR spectroscopy and its association with the clinicopathological characteristics. Mol Biol Rep, 2012, 39(9): 8955-64.
15 Guo S, Qiu L, Wang Y, et al. Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry. Analytical and Bioanalytical Chemistry, 2014, 406(18): 4357-70.
16 Ishikawa S, Tateya I, Hayasaka T, et al. Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer. PLoS ONE, 2012, 7(11) doi: 10.1371/journal.pone.0048873.e48873
17 Carpi A, Mechanick JI, Saussez S, Nicolini A. Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications. Journal of Cellular Physiology, 2010, 224(3): 612-9.
18 Yao Z, Yin P, Su D, et al. Serum metabolic profiling and features of papillary thyroid carcinoma and nodular goiter. Molecular BioSystems, 2011, 7(9): 2608-14.
19 Putluri N, Shojaie A, Vasu VT, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res, 2011, 71(24): 7376-86.
20 Jimenez B, Mirnezami R, Kinross JM, et al. 1H HR-MAS NMR spectroscopy of tumor induced local metabolic “field-effects” enables colorectal cancer staging and prognostication. J Proteome Res, 2012, 12(2): 959-68.
21 Mal M, Koh PK, Cheah PY, et al. Metahotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Anal Bioanal Chem, 2012, 403(2): 483-93.
22 Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med, 2002, 8(12): 1439-45.
23 Hua HY, Jia YH, Zhang HS, et al. Metabolomic study on plasma from patients with angina pectoris due to coronary heart disease with three kinds of blood-stasis syndrome. J Tropical Med, 2010, 10(3): 258-60, 79.
25 Shah SH, Sun JL, Stevens RD, et al. Baseline metaholomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J, 2012, 163(5): 844-50.
26 Vaarhorst AA, Verhoeven A, Weller CM, et al. A metabolomic profile is associated with the risk of incident coronary heart disease. Am Heart J, 2014, 168(1): 45-52.
27 Brindle JT, Nicholson JK, Schofield PM, et al. Application of chemometrics to 1H-NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst, 2003, 128(1): 32-6.
28 Lu Y, Wang G, Hao H, et al. Gas chromatography/time-of-flight mass spectrometry based metabonomic approach to dfferentiating hypertension-and age-related metabolic variation in spontaneously hypertensive ruts. Rapid Commun Mass Spectrom, 2008, 22(18): 2882-8.
29 Bang H, Li Y, Xie J. Urine metabonomic study on hypertension patients of ascendant hyperactivity of Gan Yang syndrome by high performance liquid chromatography coupled with time of flight mass spectrometry. Chin J Integra Tradh Western Med, 2012, 32(3): 333-7.
30 Sabatine MS, Liu E, Morrow DA, et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation, 2005, 112 (25): 3868-75.
31 Lewis GD, Wei RU, Liu E, et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Investig, 2008, 118(10): 3503.
32 Carraro S, Rezzi S, Reniem F, et al. Metabolomics applied to exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med, 2007, 175(10): 986-90.
33 Saude EJ, Skappak CD, Regush S, et al. Mteabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J Allergy Clin Immunol, 2011, 127(3): 757-64.
Wu MZ, Zhao CX, Xu GW, et al. Blood metabonomics study on asthma patients with abnormal Sawda syndrome treated with LC-MS system by uighur medicine. World Sci Technol (Modernization Tradit Chinese Med Materia Madica
), 2009, (1): 134-41.
35 Reid JS, Baurecht H, Stuckler F, et al. Integrative genetic and metabolic profiling analysis suggests altered phosphatidylcholine metabolism in asthma. Allergy, 2013, 68(5): 629-36.
36 Basanta M, Jarvis RM, Xu Y, et al. Non-invasive metabolomic analysis of breathing using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analys, 2010, 135(2): 315-20.
37 Van Berkel JJ, Dallinga JW, Moller GM, et al. A profile of volatile organic compounds in breath discriminate COPD patients from controls. Respir Med, 2010, 104(4): 557-63.
38 Paige M, Burdick MD, Kim S, et al. Pilot analysis of the plasma metabolite profiles associated with emphysematous chronic obstructive pulmonary disease phenotype. Biochem Biophys Res Commin, 2011, 413(4): 588-93.
39 Ubhi BK, Cheng KK, Dong J, et al. Targeted metabolomics indentifies pertuebations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst, 2012, 8(12): 3125-33.
40 Duarte IF, Rocha CM, Gil AM. Metabolic profiling of biofluids: potential in lung cancer screening and diagnosis. Expert Rev Mol Diagn, 2013, 13 (7): 737-48.
41 Zhou L, Wang Q, Yin P, et al. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem, 2012, 403(1): 203-13.
43 McClay JL, Adkins DE, Isern NG, et al. (1)H nuclear magnetic resonance metabolomics analysis indentifies novel urinary biomarkers for lung function. J Ptroteome Res, 2010, 9(6): 3083-90.
44 Zhou XP, Li H. Application and reflection on metabonomics in the treating of rheumatic disease from TCM perspective. J Nanjing Univ Tradit Med, 2015, 31(1): 4-7.
45 Hu GF, Xiao LW, Tong PJ. Application and joint fluid metabonomics to diagnosis and cold-heat symptom complex typing in patients with rheumatoid arthritis. N Trad Chin Orthop Trauma, 2015, 27(1): 5-8.
46 Hu JB, Gu HC, Ding ZS, et al. Study on application of HPLE-Q-TOF/MS-based metabonomics on the interventional effect of Formula for Detoxication, Removing Stasis and Nourishing Yin on SLE. China J Chinese Materia Medica, 2013, 38(21): 3747-52.